BioSpace News Archive

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced they have entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications.

Medivir AB announces that the Annual Report for 2023 now is available at the company’s website.

GenSight Biologics today announced its financial calendar for 2024.

Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will present a poster at the American Association for Cancer Research Annual Meeting (AACR) 2024 being held on April 5-10, 2024.

Eilean Therapeutics LLC is pleased to announce the clearance from the Human Research Ethics Committee in Australia for lomonitinib (ZE46-0134) allowing the company to proceed with a Phase I clinical trial in relapsed/refractory (R/R) AML.

Immunocore Holdings plc, a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, announced that management will participate in the following investor conferences in April.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2024 after the market closes on Monday, April 29, 2024.

Mural Oncology plc announced that on April 1, the Company granted to four newly hired employees non-statutory stock options to purchase an aggregate of 25,675 ordinary shares of the Company and restricted stock units with respect to an aggregate of 13,825 ordinary shares of the Company.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to one new employee with a grant date of April 1, 2024, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the commercial launch of its newest Light Adjustable Lens, the LAL+.